IADR Abstract Archives
Recent of Biomarker Tools - Point of Care Chair Side Oral Fluid Immunotests for aMMP8 to Determine Peri Implant Diseases
Objectives: It is challenging to evaluate oral fluids such as peri-implantitis fluids (PISF). Issues relating to hosts and microbial factors could influence biomarkers expression, release and levels. To attain best results, highly sophisticated methods of analysis are required, with high levels of specificity and sensitivity. We define here a recent chair-side/point of care (PoC) lateral-flow immunotests (ImplantSafe®) for detecting active form of MMP-8 in PISF and quantitated by analyse reader (ORALyzer®). The objective of study was to show the effectiveness of promising biomarker test (ImplantSafe®/ORALyzer®) to differentiate between peri-implantitis and healthy sites.
Methods: Peri-implantitis (n = 29), and healthy controls (n = 32) Both X-rays and clinical parameters have diagnosed, such as probing pocket depth (PPD), bleeding on probing (BOP), and plaque index (PI). All have diagnosed aMMP-8 by ImplantSafe® visual test, and quantitated by ORALyzer®. We analyzed quantitatively aMMP-8 by immunofluorometric assay (IFMA) and all forms of MMP-2 and MMP-9 densitometrically by quantitated gelatin zymography.
Results: Level of aMMP-8 in peri-implatitis site (n = 29) analyzed by ImplantSafe visually positive (+) and quantitated by (ORALyzer®) >20 ng/ml, (124.60 ± 22.50 ng/ml) differing from health site (n = 32) all having low aMMP-8 visually negative (−) <20 ng/ml, (18.60 ± 3.46 ng/ml). PoC detected in 5 min by ImplantSafe. Likewise, elevated level of aMMP-8 detected by immunofluorometric assay (IFMA) 100% in all peri-implatitis site >20 ng/ml, whereas all healthy site were <20 ng/ml. Any forms or total MMP-9 and -2 did not significantly differentiate peri-implantitis and healthy sites.
Conclusions: Based on our results, increased levels of aMMP-8 in PISF was determined to be correlated with clinical and radiographic parameters. ImplantSafe® is and so the first clinically validated commercially available diagnostic, prognostic, and preventive chair-side/PoC -technologie for peri-implant diseases.
Methods: Peri-implantitis (n = 29), and healthy controls (n = 32) Both X-rays and clinical parameters have diagnosed, such as probing pocket depth (PPD), bleeding on probing (BOP), and plaque index (PI). All have diagnosed aMMP-8 by ImplantSafe® visual test, and quantitated by ORALyzer®. We analyzed quantitatively aMMP-8 by immunofluorometric assay (IFMA) and all forms of MMP-2 and MMP-9 densitometrically by quantitated gelatin zymography.
Results: Level of aMMP-8 in peri-implatitis site (n = 29) analyzed by ImplantSafe visually positive (+) and quantitated by (ORALyzer®) >20 ng/ml, (124.60 ± 22.50 ng/ml) differing from health site (n = 32) all having low aMMP-8 visually negative (−) <20 ng/ml, (18.60 ± 3.46 ng/ml). PoC detected in 5 min by ImplantSafe. Likewise, elevated level of aMMP-8 detected by immunofluorometric assay (IFMA) 100% in all peri-implatitis site >20 ng/ml, whereas all healthy site were <20 ng/ml. Any forms or total MMP-9 and -2 did not significantly differentiate peri-implantitis and healthy sites.
Conclusions: Based on our results, increased levels of aMMP-8 in PISF was determined to be correlated with clinical and radiographic parameters. ImplantSafe® is and so the first clinically validated commercially available diagnostic, prognostic, and preventive chair-side/PoC -technologie for peri-implant diseases.